Company intelligence / Profile preview

Nano24

Israel

Ownership: Private
Development stage: Phase 2

Overview

Nano24 has developed a novel exosome-based therapy—EXO-CD24—for immune hyperactivation syndromes such as ARDS and sepsis. The lead program has been clinically tested in more than 250 patients with ARDS and demonstrated safety and efficacy over four years of follow-up. The company’s Phase IIb randomized controlled trial for mild-moderate ARDS began in July 2023 and remains ongoing as of early 2025. EXO-CD24 aims to modulate the immune response without compromising host defense against infections. No specific cure currently exists for these conditions; thus, this represents a potential breakthrough therapy.[1][4][6]

Therapeutic areas: ImmunologyPulmonologyInfectious Diseases
Modalities: Exosome-based therapeuticsimmunomodulators (specifically CD24-enriched exosomes)[1][2][6]
Industry: Biotech

Drug pipeline

1 asset

EXO-CD24

Phase 2

Indications: Acute Respiratory Distress Syndrome (ARDS), Cytokine storm

Beyond the preview

Go deeper on Nano24.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nano24.

Explore the full profile